This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Heather Bax
Postdoctoral Research Fellow at King's College London


Prof Sophia Karagiannis’ laboratory, King’s College London, Dr Heather Bax undertook multidisciplinary research on the ground-breaking pre-clinical development of the first-in-class IgE antibody, MOv18 IgE, for the treatment of Folate Receptor alpha (FRα)-expressing ovarian cancers. She established and implemented several clinical trial assays to support the now successfully completed first-in-man, Phase I clinical trial of MOv18 IgE. She also led the pre-clinical studies of CSPG4 IgE, another IgE therapeutic candidate targeting melanoma. Heather currently supports a translational research programme funded by the King’s College London spinout Epsilogen Ltd, the first immuno-oncology company focusing on the next generation of IgE-based antibodies for the treatment of solid tumours.

Agenda Sessions

  • Jim Huston Science Talent Award Winner Presentation: IgE Class Antibody Therapeutics for Cancer